Levosulpiride 25mg
Levosulpiride 25mg — the levo-isomer of sulpiride, acting as a selective peripheral and central D2/D3 receptor antagonist. Blocks dopaminergic inhibition of GI peristalsis (prokinetic) and dopamine-mediated nausea at the CTZ (anti-emetic). At the standalone 25mg tablet dose, levosulpiride can be dosed more flexibly than in fixed combinations, allowing titration from 25mg once daily up to 25mg three times daily. See PANSWING™ LS for full mechanism detail.
Functional dyspepsia, delayed gastric emptying, GORD with motility component, post-prandial bloating, nausea and vomiting, and diabetic gastroparesis. As a standalone tablet, SULPRIX 25 allows prescribers to use levosulpiride with any PPI independently — important when a different PPI is clinically preferred or when prokinetic therapy alone is sufficient without acid suppression.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
SULPRIX 25 provides prescribers flexibility not possible with fixed PPI-levosulpiride combinations — they can pair levosulpiride with rabeprazole, esomeprazole, or any PPI independently, and titrate the prokinetic dose separately from the acid-suppressive dose. This prescribing flexibility is valued by gastroenterologists who prefer to optimise each component independently.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.